Inhibitory effect of a potent and selective cytosolic phospholipase A2alpha inhibitor RSC-3388 on skin inflammation in mice.
Cytosolic phospholipase A2alpha (cPLA2alpha) preferentially hydrolyzes membrane phospholipids containing arachidonic acid, resulting in the biosynthesis of eicosanoids such as prostaglandins and leukotrienes. To examine the contribution of cPLA2alpha to skin inflammation, we evaluated the effect of (E)-N-[(2S,4R)-4-[N-(biphenyl-2-ylmethyl)-N-2-methylpropylamino]-1-[2-(2,4-difluorobenzoyl)benzoyl]pyrrolidin- 2-yl]methyl-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl) phenyl]acrylamide (RSC-3388), a potent and selective cPLA2alpha inhibitor, on 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced ear inflammation and mite antigen-induced dermatitis in mice. Topical application of RSC-3388 showed a significant inhibitory activity against TNCB-induced ear swelling and eicosanoid production in mice. Comprehensive expression analysis using Gene-Chip technology and subsequent experiments concerning mRNA and protein expression demonstrated that RSC-3388 clearly reduced the levels of interleukin-1beta, macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta in a TNCB-induced mouse model. In addition, RSC-3388 ointment significantly alleviated atopic dermatitis-like skin lesions induced by repeated application of mite antigen. Furthermore, increased expression of cPLA(2)alpha, assessed by anti-phospho-cPLA2alpha antibody, was observed in the skin lesions of mite-antigen-induced dermatitis. These results indicate that cPLA2alpha is involved in the development of skin inflammation in mice, and RSC-3388 is expected to be useful for the treatment of inflammatory skin disorders such as atopic dermatitis.
Yamamoto
Mina
M
Discovery Research Laboratory, Shionogi and Co., Ltd., Osaka, Japan.
Haruna
Takayo
T
Imura
Kinichi
K
Hikita
Ichiro
I
Furue
Yoko
Y
Higashino
Kenichi
K
Gahara
Yoshinari
Y
Deguchi
Masashi
M
Yasui
Kiyoshi
K
Arimura
Akinori
A
D000178:Acrylamides / Q000494:pharmacology*; D000279:Administration, Cutaneous; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology; D054405:Chemokine CCL3 / Q000187:drug effects / Q000378:metabolism; D054407:Chemokine CCL4 / Q000187:drug effects / Q000378:metabolism; D003872:Dermatitis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D054513:Group IV Phospholipases A2 / Q000037:antagonists & inhibitors*; D053583:Interleukin-1beta / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D020411:Oligonucleotide Array Sequence Analysis; D010853:Picryl Chloride / Q000633:toxicity; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000473:pathology; D045162:Thiazolidinediones / Q000494:pharmacology*
D000178:Acrylamides; D039741:Antigens, Dermatophagoides; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D004791:Enzyme Inhibitors; D053583:Interleukin-1beta; C529994:N-(-4-(N-(biphenyl-2-ylmethyl)-N-2-methylpropylamino)- 1-(2-(2,4-difluorobenzoyl)benzoyl)pyrrolidin- 2-yl)methyl-3-(4-(2,4-dioxothiazolidin-5-ylidenemethyl) phenyl)acrylamide; D012333:RNA, Messenger; D045162:Thiazolidinediones; D054513:Group IV Phospholipases A2; D010853:Picryl Chloride